vimarsana.com

Page 3 - ஹார்ட் ஸ்காட் ரோடினோ நம்பிக்கையற்ற மேம்பாடுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Meredith sells broadcasting arm Local Media Group for $2 7B; National Media Group to spin off as publicly traded company

  Meredith sells broadcasting arm Local Media Group for $2.7B; National Media Group to spin off as publicly traded company BY BUSINESS RECORD STAFF Monday, May 3, 2021 11:05 AM Meredith Corp. today announced that it has agreed to sell its Local Media Group to Gray Television Inc. for $2.7 billion in cash and will focus exclusively on its National Media Group portfolio. Under the terms of the transaction, Meredith s National Media Group will be spun off to shareholders as a stand-alone publicly traded company retaining the Meredith name, with shareholders receiving cash consideration per share of approximately $14.50 and 1-for-1 equity share in post-close Meredith. The transaction was unanimously approved by Meredith s and Gray s boards.

Meredith Corp (MDP) To Sell Local Media Group to Gray Television (GTN) For $2 7 Billion

Meredith Corp (MDP) To Sell Local Media Group to Gray Television (GTN) For $2 7 Billion
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the . CRISPR Therapeutics AGApril 26, 2021 GMT BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE)   Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT). CTX001 was previously granted PRIME designation for the treatment of sickle cell disease (SCD) in 2020.

FERC Approves AVANGRID s Proposed PNM Resources Merger

FERC Approves AVANGRID’s Proposed PNM Resources Merger Read full article Oops! Merger on track to close in the second half of 2021 AVANGRID, Inc. (NYSE: AGR), a leading sustainable energy company, announced today that it has received Federal Energy Regulatory Commission (FERC) approval for its proposed PNM Resources (NYSE: PNM) merger. This approval is an important step in the merger process, which will bring together two companies focused on delivering safe, reliable and clean energy for customers and communities, said Dennis V. Arriola, CEO of AVANGRID. The merger will further AVANGRID’s growth in both clean energy distribution and transmission, as well as expand our leadership position in renewables.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.